Sign in
CompletedPhase 1

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

Key facts

Who runs it
GlaxoSmithKline
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
123 people enrolled
Started
11 Dec 2023
Ended
16 Jun 2026
Type of study
Interventional, 15 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • GSK4024484C
  • Placebo
Record updated
8 July 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Participant must be 18 to 60 years of age inclusive, at the time of signing the informed consent
  • Participants who are considered healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac assessment
  • A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, or outside the normal reference range for the population being studied, may be included only if the Investigator considers, that the finding is unlikely to introduce additional risk factors for the participant and will not interfere with the study procedures or endpoints
  • ALT (Alanine transaminase) and AST (Aspartate transaminase) within the normal range at screening
  • Total bilirubin within the normal range unless the participant is known to have Gilbert's syndrome
  • Body weight ≥50kg, and BMI within the range 19 to 32 kilogram per square metre (kg/m\^2) inclusive
  • Male participants and female participants who are not of child bearing potential
  • The participant is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions

Who cannot take part

  • An average weekly alcohol intake of >14 units a week within 6 months prior to the study. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits
  • Evidence of previous myocardial infarction or any clinically significant conduction abnormality such as (including but not specific to left complete bundle branch block, AV block [2nd degree or higher], WPW syndrome). Long standing RBBB is permitted
  • Past or intended use of over-the-counter or prescription medication, including herbal medications, CBD-based products, PPIs or H2 antagonists within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is the longest) prior to dosing. Other concomitant medication may be considered on a case by case basis by the investigator in consultation with the medical monitor. Paracetamol is permitted (capped at ≤2 grams/day)
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day
  • Current enrolment or past participation (within the last 30 days before planned first dose in this study) in any other clinical study involving an investigational study intervention or any other type of medical research
  • Participants previously dosed in this study
  • Presence of HBsAg [or HBcAb] at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C RNA (ribonucleic acid) test result at screening or within 3 months prior to first dose of study intervention
  • Positive pre-study drug/alcohol screen
  • Carbon monoxide levels indicative of smoking or more than 10 pack year history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening
  • Use of known recreational drugs or drugs of abuse
  • History or presence of cardiovascular (including hypertension), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data in the opinion of the investigator
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Heart rate <40 or >100 beats per minute (bpm)
  • Positive HIV antibody test
  • Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates participation in the study
  • A positive confirmation of COVID-19 infection according to local procedures
  • QTcF (Fridericia's formula) >450 msec based on average of triplicate ECGs. The QTcF is the QT interval corrected for heart rate according to QTcF
  • Presence or history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome
  • More than 100 ventricular ectopic complexes in 24 hrs by Holter screening or any other clinically significant Holter abnormalities determined by the investigator
  • Participation in the study that would result in loss of blood or blood products in excess of 500 mL within a 56-day period

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.

The 15 groups in the trial

  • 6 mg single ascending dose (SAD) GroupTreatment being tested

    Participants receive a 6 mg single dose of GSK4024484, in a fasted state.

    Treatment: GSK4024484C

  • 12 mg SAD GroupTreatment being tested

    Participants receive a 12 mg single dose of GSK4024484 in a fasted state.

    Treatment: GSK4024484C

  • 24 mg SAD GroupTreatment being tested

    Participants receive a 24 mg single dose of GSK4024484 in a fasted state.

    Treatment: GSK4024484C

  • 48 mg SAD GroupTreatment being tested

    Participants receive a 48 mg single dose of GSK4024484 in a fasted state.

    Treatment: GSK4024484C

  • 96 mg SAD GroupTreatment being tested

    Participants receive a 96 mg single dose of GSK4024484 in a fasted state.

    Treatment: GSK4024484C

  • 192 mg SAD GroupTreatment being tested

    Participants receive a 192 mg single dose of GSK4024484, in a fasted state.

    Treatment: GSK4024484C

  • Food Effect GroupTreatment being tested

    Participants receive a single study dose of GSK4024484 in a fed state.

    Treatment: GSK4024484C

  • 300 mg SAD GroupTreatment being tested

    Participants receive a 300 mg single dose of GSK4024484, in a fasted state.

    Treatment: GSK4024484C

  • 400 mg SAD GroupTreatment being tested

    Participants receive a 400 mg single dose of GSK4024484, in a fasted state.

    Treatment: GSK4024484C

  • Optional SAD GroupTreatment being tested

    Participants may be included in this group, to allow flexibility if the dose escalation needs modification or a dose level needs to be added or repeated.

    Treatment: GSK4024484C

  • Placebo SAD GroupPlacebo, for comparison

    Participants receive placebo in a fed or fasted state.

    Treatment: Placebo

  • 150 mg multiple ascending doses (MAD) GroupTreatment being tested

    Participants receive 150 mg per day of GSK4024484 during 3 subsequent days (450 mg total).

    Treatment: GSK4024484C

  • 300 mg MAD GroupTreatment being tested

    Participants receive 300 mg per day of GSK4024484 during 3 subsequent days (900 mg total).

    Treatment: GSK4024484C

  • Optional MAD GroupTreatment being tested

    Participants may be included in this group, to allow flexibility if the dose escalation needs modification or a dose level needs to be added or repeated.

    Treatment: GSK4024484C

  • Placebo MAD GroupPlacebo, for comparison

    Participants receive placebo during 3 subsequent days.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Randomised, Double Blind Placebo-controlled, First Time in Human Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Oral Doses and Food Effect of GSK4024484 in Healthy Adult Participants.
Record updated
8 July 2026